KYNB: the balance sheet

MyFinsight

For the year ending 2025-12-31, KYNB has $119,594K in assets. $115,119K in debts. $47,872K in cash and cash equivalents.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Balance Sheets	2025-12-31
Cash and cash equivalents	47,872
Short-term investments	41,106
Accounts receivable, net	216
Inventories	3,743
Prepaid expenses and other current assets	6,136
Current assets held for sale	0
Total current assets	99,073
Long-term investments	20,160
Other assets	361
Long-term assets held for sale	0
Total assets	119,594

Accounts payable	3,745
Accrued and other current liabilities	20,183
Deferred revenue	5,314
Current liabilities held for sale	0
Total current liabilities	29,242
Product development obligations	19,560
Deferred revenue, net of current	255
Senior secured term loan facilities, non-current	0
Liability related to sale of future revenues, non-current	65,980
Other long-term liabilities	82
Long-term liabilities held for sale	0
Total liabilities	115,119
Redeemable non-controlling interests	21,480
Common stock, 0.01 par value 225,000 shares authorized at december 31, 2025 and 2024 4,047 and 4,037 shares issued and outstanding at december 31, 2025 and 2024	1,012
Additional paid-in capital	1,677,179
Accumulated other comprehensive loss	-2,182
Accumulated deficit	-1,706,047
Total stockholders' deficit attributable to kyntra bio	-30,038
Nonredeemable non-controlling interests	13,033
Total deficit	-17,005
Total liabilities, redeemable non-controlling interests and deficit	119,594

Unit: Thousand (K) dollars